Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient

Infect Dis Clin North Am. 2019 Jun;33(2):593-609. doi: 10.1016/j.idc.2019.02.007.

Abstract

Patients with hematologic malignancy or those who undergo hematopoietic stem cell transplantation experience variable degrees of immunosuppression, dependent on underlying disease, therapy received, time since transplant, and complications, such as graft-versus-host disease. Vaccination is an important strategy to mitigate onset and severity of certain vaccine-preventable illnesses, such as influenza, pneumococcal disease, or varicella zoster infection, among others. This article highlights vaccines that should and should not be used in this patient population and includes general guidelines for timing of vaccination administration and special considerations in the context of newer therapies, recent vaccine developments, travel, and considerations for household contacts.

Keywords: Cancer; Hematologic; Stem cell transplant; Vaccines.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Clinical Trials as Topic
  • Hematologic Neoplasms / complications*
  • Hematologic Neoplasms / immunology
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunization Schedule
  • Immunogenicity, Vaccine
  • Immunosuppression Therapy
  • Practice Guidelines as Topic
  • Risk Factors
  • Vaccination / adverse effects
  • Vaccination / statistics & numerical data*
  • Vaccines / administration & dosage*
  • Vaccines / adverse effects

Substances

  • Vaccines